1,290 results on '"Palladini, Giovanni"'
Search Results
2. Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy
3. Correction to: Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy
4. Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis
5. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study
6. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
7. Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy
8. Diagnosis and Treatment of AL Amyloidosis
9. Nanobodies counteract the toxicity of an amyloidogenic light chain by stabilizing a partially open dimeric conformation
10. Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies
11. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
12. Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study
13. An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis
14. Renal alterations in cats (Felis catus) housed in shelters and affected by systemic AA-amyloidosis: Clinicopathological data, histopathology, and ultrastructural features
15. Response matters in light chain amyloidosis, whatever it takes
16. Inclusion criteria of clinical trials select patients with AL amyloidosis with favorable outcome and exclude almost one half of the real-life population.
17. Prognostic impact of cytogenetic abnormalities by FISH in systemic AL amyloidosis in the era of daratumumab and bortezomib-based frontline combination regimens
18. Proposed hematologic progression criterion in patients with AL amyloidosis.
19. Bone marrow-free sequencing of M protein genes: a liquid biopsy approach in monoclonal gammopathies
20. A phase II study of daratumumab and pomalidomide in previously treated patients with AL amyloidosis
21. Phase 1b study evaluating the safety and efficacy of ABBV-383 monotherapy in patients with light chain amyloidosis
22. New reference ranges of free light chain ratio: impact on clinical practice in AL and ATTRwt amyloidosis
23. Diagnostic performance of [18F]-Florbetaben PET for the detection of cardiac involvement in AL amyloidosis: first results of the MoRBiDA trial
24. Long term outcome of a sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis
25. N-glycosylation of clonal immunoglobulin light chains as a risk factor for AL amyloidosis: Benchmarking N-glycosylation prediction tools
26. The Pavia Amyloidosis Research and Treatment Center’s 25-year experience in molecular diagnostics for hereditary amyloidoses
27. Biomarker-based renal response and progression criteria in AA amyloidosis: results from the testing cohort of the Pavia-Heidelberg study
28. Nanobodies as novel tools to target cardiac light chain amyloidosis
29. Evolution over time of echocardiographic features in patients with wild-type transthyretin cardiac amyloidosis
30. Prevalence and evolution over time of 12-lead ECG and Holter monitoring features in patients with wild-type transthyretin cardiac amyloidosis
31. International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction
32. Deciphering the conformational landscape of amyloidogenic lambda light chains associated with AL amyloidosis
33. Determinants of amyloidogenic behavior in AL amyloidosis patient-derived AL55 light chain: Insights from structural and biophysical studies
34. The Cryo-EM structure of renal amyloid fibrils suggests structurally homogeneous multiorgan aggregation in AL amyloidosis
35. Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival
36. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms
37. How I treat AL amyloidosis
38. Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: an analysis of six use cases
39. Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter
40. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.
41. International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction.
42. Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis.
43. The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis.
44. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group
45. Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network
46. Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network
47. Learning From Trials
48. Advances in the treatment of light chain amyloidosis
49. Search for AL amyloidosis risk factors using Mendelian randomization
50. 4D flow evaluation of blood non-Newtonian behavior in left ventricle flow analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.